Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 49-54 , April 2008

18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study

  • Judith van Loon

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Judith van Loon, MAASTRO Clinic, Dr. Tanslaan 12, NL-6229 ET Maastricht, The Netherlands.
    • ,
  • Claudia Offermann

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Geert Bosmans

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Rinus Wanders

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • André Dekker

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Jacques Borger

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Michel Oellers

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Anne-Marie Dingemans

      Affiliations

    • Department of Pulmonology, University Hospital Maastricht, The Netherlands
    • ,
  • Angela van Baardwijk

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Jaap Teule

      Affiliations

    • Department of Nuclear Medicine, University Hospital Maastricht, The Netherlands
    • ,
  • Gabriel Snoep

      Affiliations

    • Department of Radiology, University Hospital Maastricht, The Netherlands
    • ,
  • Monique Hochstenbag

      Affiliations

    • Department of Pulmonology, University Hospital Maastricht, The Netherlands
    • ,
  • Ruud Houben

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (Maastro Clinic), GROW Research Institute, University Hospital Maastricht, The Netherlands

Received 11 October 2007 ,Revised 12 February 2008 ,Accepted 16 February 2008.

References 

  1. Bunn PA, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol. 1997;24:S7–69–S67–74
  2. Ihde DC. Small cell lung cancer. State-of-the-art therapy 1994. Chest. 1995;107:243S–248S
  3. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24:1057–1063
  4. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543–552
  5. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2004;CD004700
  6. Choi NC, Herndon JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998;16:3528–3536
  7. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  8. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol. 2004;71:139–146
  9. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:999–1006
  10. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  11. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  12. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  13. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol. 2005;77:5–10
  14. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys. 2005;61:649–655
  15. De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006;80:307–312
  16. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248–3254
  17. Chin R, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer. 2002;37:1–6
  18. Shen YY, Shiau YC, Wang JJ, Ho ST, Kao CH. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22:1257–1264
  19. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–345
  20. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–1620
  21. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78–84
  22. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007;57:328–333
  23. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–1723
  24. Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys. 2005;63:170–178
  25. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  26. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142–2149
  27. ICRU Report 50. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements. In Edition 1993.
  28. Bradley J, Deasy JO, Bentzen S, El-Naqa I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:1106–1113
  29. De Ruysscher D, Dehing C, Bremer RH, et al. Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients. Ann Oncol. 2007;18:909–916
  30. Lenth RV. Java Applets for Power and Sample Size In Edition retrieved November, 1, 2006. 2006.
  31. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007;
  32. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44:1911–1917
  33. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  34. Jenkins P, Salmon C, Mannion C. Analysis of the movement of calcified lymph nodes during breathing. Int J Radiat Oncol Biol Phys. 2005;61:329–334
  35. Goerres GW, Burger C, Kamel E, et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology. 2003;226:906–910
  36. Nagel CC, Bosmans G, Dekker AL, et al. Phased attenuation correction in respiration correlated computed tomography/positron emitted tomography. Med Phys. 2006;33:1840–1847
  37. Smulders SA, Gundy CM, van Lingen A, Comans EF, Smeenk FW, Hoekstra OS. Observer variation of 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography in mediastinal staging of non-small cell lung cancer as a function of experience, and its potential clinical impact. Mol Imaging Biol. 2007;9:318–322
  38. Cascade PN, Gross BH, Kazerooni EA, et al. Variability in the detection of enlarged mediastinal lymph nodes in staging lung cancer: a comparison of contrast-enhanced and unenhanced CT. AJR Am J Roentgenol. 1998;170:927–931

PII: S0167-8140(08)00113-8

doi: 10.1016/j.radonc.2008.02.019

Radiotherapy & Oncology
Volume 87, Issue 1 , Pages 49-54 , April 2008

Article Tools

* Image Usage & Resolution